The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia

Journal of Palliative Medicine

Volumn 16, Issue 6, 2013, Pages 616-622

  Salpeter, Shelley R ^a   Buckley, Jacob S ^b   Bruera, Eduardo ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; METHADONE;

ADULT; AGED; ANALGESIA; ARTICLE; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; HOSPICE CARE; HUMAN; HYPERALGESIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; PAIN; PAIN ASSESSMENT; PALLIATIVE THERAPY; RETROSPECTIVE STUDY; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CALIFORNIA; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID AGONISTS; FEMALE; HALOPERIDOL; HOSPICE CARE; HUMANS; HYPERALGESIA; MALE; MEDICAL AUDIT; METHADONE; MIDDLE AGED; N-METHYLASPARTATE; PAIN MANAGEMENT; RETROSPECTIVE STUDIES;

EID: 84878563494     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2012.0612     Document Type: Article

References (78)

1. Weschules DJ, McMath JA, Gallagher R, Alt CJ, Knowlton CH: Methadone and the hospice patient: Prescribing trends in the home-care setting. Pain Med 2003;4(3):269-276.
2. Gilson AM, Ryan KM, Joranson DE, Dahl JL: A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J Pain Symptom Manage 2004;28(2):176-188. (Pubitemid 38970078)
3. Olsen Y, Daumit GL, Ford DE: Opioid prescriptions by U.S. primary care physicians from 1992 to 2001. J Pain 2006;7(4): 225-235.
4. Hudson TJ, Edlund MJ, Steffick DE, Tripathi SP, Sullivan MD: Epidemiology of regular prescribed opioid use: Results from a national, population-based survey. J Pain Symptom Manage 2008;36(3):280-288.
5. Garcia del Pozo J, Carvajal A, Viloria JM, Velasco A, Garcia del Pozo V: Trends in the consumption of opioid analgesics in Spain: Higher increases as fentanyl replaces morphine. Eur J Clin Pharmacol 2008;64(4):411-415.
6. Borgsteede SD, Deliens L, Zuurmond WW, et al.: Prescribing of pain medication in palliative care: A survey in general practice. Pharmacoepidemiol Drug Saf 2009;18(1): 16-23.
7. Marks RM, Sachar EJ: Undertreatment of medical inpatients with narcotic analgesics. Ann Intern Med 1973;78(2):173-181.
8. Bruera E, Fox R, Chadwick S, Brenneis C, MacDonald N: Changing pattern in the treatment of pain and other symptoms in advanced cancer patients. J Pain Symptom Manage 1987;2(3):139-144. (Pubitemid 18082998)
9. Morgan JP: American opiophobia: Customary underutiliza-tion of opioid analgesics. Adv Alcohol Subst Abuse 1985/1986;5(1-2):163-173. (Pubitemid 16152858)
10. World Health Organization: Cancer Pain Relief: With a Guide to Opioid Availability, 2nd ed. Geneva: WHO, 1996.
11. American Academy of Pain Medicine and American Pain Society: The use of opioids for the treatment of chronic pain: A consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain 1997;13(1):6-8.
12. Paulozzi LJ, Budnitz DS, Xi Y: Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 2006;15(9):618-627. (Pubitemid 44404658)
13. Pappagallo M, Dickerson ED, Hulka S: Palliative care and hospice opioid dosing guidelines with breakthrough pain (BP) doses. Am J Hosp Palliat Care 2000;17(6):407-413.
14. Azoulay D, Jacobs JM, Cialic R, Mor EE, Stessman J: Opioids, survival, and advanced cancer in the hospice setting. J Am Med Dir Assoc 2011;12(2):129-134.
15. Bennett MI, Graham J, Schmidt-Hansen M, Prettyjohns M, Arnold S: Prescribing strong opioids for pain in adult palliative care: Summary of NICE guidance. BMJ 2012;344: e2806.
16. Caraceni A, Hanks G, Kaasa S, et al.: Use of opioid analgesics in the treatment of cancer pain: Evidence-based recommendations from the EAPC. Lancet Oncol 2012;13(2): e58-e68.
17. Khan MI, Walsh D, Brito-Dellan N: Opioid and adjuvant analgesics: Compared and contrasted. Am J Hosp Palliat Care 2011;28(5):378-383.
18. Lawlor P, Walker P, Bruera E, Mitchell S: Severe opioid toxicity and somatization of psychosocial distress in a cancer patient with a background of chemical dependence. J Pain Symptom Manage 1997;13(6):356-361. (Pubitemid 27280030)
19. Strasser F, Walker P, Bruera E: Palliative pain management: When both pain and suffering hurt. J Palliat Care 2005;21(2):69-79. (Pubitemid 40992255)
20. Mercadante S, Arcuri E: Hyperalgesia and opioid switching. Am J Hosp Palliat Care 2005;22(4):291-294. (Pubitemid 41039786)
21. Zimmermann C, Seccareccia D, Booth CM, Cottrell W: Rotation to methadone after opioid dose escalation: How should individualization of dosing occur? J Pain Palliat Care Pharmacother 2005;19(2):25-31. (Pubitemid 41344305)
22. U.S. Centers for Disease Control: Unintentional Drug Poisoning in the United States. 2010. www.cdc.gov/homeandrecreational safety/pdf/poison-issue- brief.pdf. (Last accessed August 5, 2012.)
23. U.S. CDC: Prescription painkiller overdoses in the US. CDC Vital Signs 2011. www.cdc.gov/vitalsigns/pdf/2011-11-vi-talsigns.pdf. (Last accessed August 15, 2012.)
24. Paulozzi LJ, Jones CM, Mack KA, Rudd RA: Vital signs: Overdoses of prescription opioid pain relievers: United States, 1999-2008. MMWR Morb Mortal Wkly Rep 2011;60(43):1487-1492.
25. Koppert W, Sittl R, Scheuber K, Alsheimer M, Schmelz M, Schuttler J: Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans. Anesthesiology 2003;99(1):152-159. (Pubitemid 36799046)
26. Mercadante S, Portenoy RK: Opioid poorly-responsive cancer pain: Part 3. Clinical strategies to improve opioid responsiveness. J Pain Symptom Manage 2001;21(4):338-354. (Pubitemid 32331888)
27. Mercadante S, Portenoy RK: Opioid poorly-responsive cancer pain: Part 2. Basic mechanisms that could shift dose response for analgesia. J Pain Symptom Manage 2001; 21(3):255-264. (Pubitemid 32192946)
28. Sotgiu ML, Valente M, Storchi R, Caramenti G, Biella GE: Cooperative N-methyl-D-aspartate (NMDA) receptor antagonism and mu-opioid receptor agonism mediate the methadone inhibition of the spinal neuron pain-related hy-peractivity in a rat model of neuropathic pain. Pharmacol Res 2009;60(4):284-290.
29. Elliott K, Minami N, Kolesnikov YA, Pasternak GW, In-turrisi CE: The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain 1994;56(1):69-75.
30. Trujillo KA: Are NMDA receptors involved in opiate-induced neural and behavioral plasticity? A review of pre-clinical studies. Psychopharmacology (Berl) 2000;151(2-3): 121-141. (Pubitemid 30646416)
31. Simonnet G, Rivat C: Opioid-induced hyperalgesia: Abnormal or normal pain? Neuroreport 2003;14(1):1-7. (Pubitemid 36160732)
32. Chu LF, Dairmont J, Zamora AK, Young CA, Angst MS: The endogenous opioid system is not involved in modulation of opioid-induced hyperalgesia. J Pain 2011;12(1):108-115.
33. Mercadante S, Ferrera P, Villari P, Arcuri E: Hyperalgesia: An emerging iatrogenic syndrome. J Pain Symptom Manage 2003;26(2):769-775. (Pubitemid 36952353)
34. Chou R, Fanciullo GJ, Fine PG, et al.: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10(2):113-130.
35. Davis MP, Walsh D: Methadone for relief of cancer pain: A review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 2001;9(2):73-83. (Pubitemid 32246453)
36. De Conno F, Groff L, Brunelli C, Zecca E, Ventafridda V, Ripamonti C. Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol 1996;14(10):2836-2842. (Pubitemid 26329671)
37. Gagnon B, Almahrezi A, Schreier G: Methadone in the treatment of neuropathic pain. Pain Res Manag 2003;8(3):149-154. (Pubitemid 37461198)
38. Doverty M, White JM, Somogyi AA, Bochner F, Ali R, Ling W: Hyperalgesic responses in methadone maintenance patients. Pain 2001;90(1-2):91-96. (Pubitemid 32146561)
39. Hjermstad MJ, Fayers PM, Haugen DF, et al.: Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: A systematic literature review. J Pain Symptom Manage 2011;41(6):1073-1093.
40. National Institutes of Health Warren Grant Magnuson Clinical Center: Pain Intensity Instruments. 2003. paincon-sortium.nih.gov/pain-scales/ numericratingscale.pdf. (Last accessed November 11, 2012.)
41. Cendan CM, Pujalte JM, Portillo-Salido E, Baeyens JM: An-tinociceptive effects of haloperidol and its metabolites in the formalin test in mice. Psychopharmacology (Berl) 2005; 182(4):485-493. (Pubitemid 41464629)
42. Colclough G, McLarney JT, Sloan PA, et al.: Epidural halo-peridol enhances epidural morphine analgesia: Three case reports. J Opioid Manag 2008;4(3):163-166.
43. Entrena JM, Cobos EJ, Nieto FR, Cendan CM, Baeyens JM, Del Pozo E: Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: Role of sigma-1 receptors. Psycho-pharmacology (Berl) 2009;205(1):21-33.
44. Leong LB, Kelly AM: Are butyrophenones effective for the treatment of primary headache in the emergency department? CJEM 2011;13(2):96-104.
45. Dalal S, Bruera E: Assessing cancer pain. Curr Pain Headache Rep 2012;16(4):314-324.
46. PoPCRN: The population-based Palliative Care Research Network (PoPCRN) Hospice Pharmacy Cost Study: May 1, 2002-September 30, 2002. Aggregate results 10/17/02. 2003. www.uchsc.edu/popcrn. (Last accessed September 14, 2012.)
47. Cheung L, Fitch K, Pyenson B: The costs of hospice care: An actuarial evaluation of the Medicare Hospice Benefit. 2001. www.cprisksolutions.com/ Articles/Thecostofhospicecare.pdf. (Last accessed September 14, 2012.)
48. Curry EA, 3rd, Palla S, Hung F, Arbuckle R, Bruera E: Prescribing patterns and purchasing costs of long-acting opioids over nine years at an academic oncology hospital. Am J Health Syst Pharm 2007;64(15):1619-1625. (Pubitemid 47173541)
49. Mercadante S, Casuccio A, Fulfaro F, et al.: Switching from morphine to methadone to improve analgesia and tolera-bility in cancer patients: A prospective study. J Clin Oncol 2001;19(11):2898-2904. (Pubitemid 32538200)
50. Bruera E, Sweeney C: Methadone use in cancer patients with pain: A review. J Palliat Med 2002;5(1):127-138. (Pubitemid 34111584)
51. Bruera E, Palmer JL, Bosnjak S, et al.: Methadone versus morphine as a first-line strong opioid for cancer pain: A randomized, double-blind study. J Clin Oncol 2004;22(1):185-192. (Pubitemid 41095131)
52. Mannino R, Coyne P, Swainey C, Hansen LA, Lyckholm L: Methadone for cancer-related neuropathic pain: A review of the literature. J Opioid Manag 2006;2(5):269-276.
53. Nicholson AB: Methadone for cancer pain. Cochrane Database Syst Rev 2007(4):CD003971.
54. Parsons HA, de la Cruz M, El Osta B, et al.: Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer 2010;116(2):520-528.
55. Pollock AB, Tegeler ML, Morgan V, Baumrucker SJ: Morphine to methadone conversion: An interpretation of published data. Am J Hosp Palliat Med 2011;28(2):135-140.
56. Mercadante S, Caraceni A: Conversion ratios for opioid switching in the treatment of cancer pain: A systematic review. Palliat Med 2011;25(5):504-515.
57. Mercadante S, Bruera E: The effect of age on opioid switching to methadone: A systematic review. J Palliat Med 2012;15(3):347-351.
58. Daeninck PJ, Bruera E: Opioid use in cancer pain. Is a more liberal approach enhancing toxicity? Acta Anaesthesiol Scand 1999;43(9):924-938. (Pubitemid 29472768)
59. Vorobeychik Y, Chen L, Bush MC, Mao J: Improved opioid analgesic effect following opioid dose reduction. Pain Med 2008;9(6):724-727.
60. Baron MJ, McDonald PW: Significant pain reduction in chronic pain patients after detoxification from high-dose opioids. J Opioid Manag 2006;2(5):277-282.
61. Mao J, Price DD, Mayer DJ: Mechanisms of hyperalgesia and morphine tolerance: A current view of their possible interactions. Pain 1995;62(3):259-274.
62. Ossipov MH, Lai J, King T, et al.: Antinociceptive and nociceptive actions of opioids. J Neurobiol 2004;61(1):126-148. (Pubitemid 39287774)
63. Chang G, Chen L, Mao J: Opioid tolerance and hyperalgesia. Med Clin North Am 2007;91(2):199-211.
64. Guignard B, Bossard AE, Coste C, et al.: Acute opioid tolerance: Intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology 2000;93(2): 409-417. (Pubitemid 30620314)
65. Angst MS, Clark JD: Opioid-induced hyperalgesia: A qualitative systematic review. Anesthesiology 2006;104(3):570-587.
66. Silverman SM: Opioid induced hyperalgesia: Clinical implications for the pain practitioner. Pain Physician 2009; 12(3):679-684.
67. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L: A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011;14(2):145-161.
68. Lawlor PG: The panorama of opioid-related cognitive dysfunction in patients with cancer: A critical literature appraisal. Cancer 2002;94(6):1836-1853. (Pubitemid 34241124)
69. Scott CC, Chen KK: The action of 1, 1-Diphenyl-1-(Di- methylaminoisopropyl)-butanone-2, a potent analgesic agent. J Pharm Exp Therap 1946;87:63-71.
70. Ferrari A, Coccia CP, Bertolini A, Sternieri E: Methadone: Metabolism, pharmacokinetics and interactions. Pharmacol Res 2004;50(6):551-559.
71. Lugo RA, Satterfield KL, Kern SE: Pharmacokinetics of meth-adone. J Pain Palliat Care Pharmacother 2005;19(4):13-24.
72. Chhabra S, Bull J: Methadone. Am J Hosp Palliat Care 2008;25(2):146-150.
73. Fredheim OM, Moksnes K, Borchgrevink PC, Kaasa S, Dale O: Clinical pharmacology of methadone for pain. Acta An-aesthesiol Scand 2008;52(7):879-889. (Pubitemid 351951756)
74. Daeninck PJ, Bruera E: Reduction in constipation and laxative requirements following opioid rotation to methadone: A report of four cases. J Pain Symptom Manage 1999;18(4): 303-309. (Pubitemid 29469709)
75. Mancini IL, Hanson J, Neumann CM, Bruera ED: Opioid type and other clinical predictors of laxative dose in advanced cancer patients: A retrospective study. J Palliat Med 2000;3(1):49-56. (Pubitemid 30262887)
76. Compton P, Charuvastra VC, Ling W: Pain intolerance in opioid-maintained former opiate addicts: Effect of long-acting maintenance agent. Drug Alcohol Depend 2001;63(2): 139-146. (Pubitemid 32488928)
77. Wolff K: Characterization of methadone overdose: Clinical considerations and the scientific evidence. Ther Drug Monit 2002;24(4):457-470. (Pubitemid 34857897)
78. Shields LB, Hunsaker Iii JC, Corey TS, Ward MK, Stewart D: Methadone toxicity fatalities: A review of medical examiner cases in a large metropolitan area. J Forensic Sci 2007;52(6):1389-1395. (Pubitemid 350243438)